RVIV · Reviv3 Procare Co - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.29M | $8.13M | $6.86M | $7.73M | $6.92M | $5.85M | $8.42M | $6.47M | $6.11M | $6.73M |
| Cost of Revenue | $2.25M | $2.60M | $2.22M | $2.23M | $1.96M | $1.70M | $1.69M | $1.85M | $363.9K | $112.8K |
| Gross Profit | $5.04M | $5.54M | $4.63M | $5.50M | $4.97M | $4.15M | $6.26M | $4.62M | $4.65M | $5.04M |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $433.0K | $494.2K | $433.3K | $434.6K | $392.4K | $486.4K | $625.3K | $547.5K | $560.2K | $232.6K |
| Total Operating Expenses | $4.83M | $4.63M | $4.22M | $4.83M | $4.38M | $4.29M | $4.99M | $4.73M | $4.47M | $4.05M |
| D&A | $27.3K | $25.7K | $62.1K | $34.4K | $45.7K | $12.9K | $27.8K | $27.6K | $28.2K | $2.1K |
| Operating Income | $214.2K | $903.1K | $411.7K | $672.9K | $583.1K | ($140.7K) | $1.26M | ($103.9K) | $173.8K | $985.0K |
| Interest Expense | $1.4K | $1.3K | $1.3K | $1.3K | $1.5K | - | $1.6K | $1.5K | $1.6K | $1.8K |
| Income Tax | $64.3K | $233.1K | $115.1K | $67.3K | $53.1K | $0 | $364.4K | ($827.4K) | $66.0K | $261.0K |
| Net Income | $203.0K | $704.9K | $334.3K | $633.7K | $576.7K | ($109.8K) | $1.02M | $781.1K | $154.5K | $726.9K |
| EPS - Basic | $0.03 | $0.10 | $0.05 | $0.10 | $0.09 | ($0.02) | $0.01 | $0.13 | $0.00 | $0.01 |
| EPS - Diluted | $0.02 | $0.09 | $0.04 | $0.08 | $0.07 | ($0.02) | $0.00 | $0.04 | $0.00 | $0.00 |
Balance Sheet
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.52M | $4.98M | $4.09M | $4.77M | $4.74M | $4.15M | $3.25M | $4.89M | $5.06M | $4.83M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | $3.93M | $4.72M | $3.89M | $2.53M | $2.74M | $3.27M | $3.39M | $3.44M | $2.07M | $1.31M |
| Accounts Payable | $1.23M | $1.84M | $2.39M | $866.6K | $896.4K | $1.37M | $967.6K | $1.89M | $1.08M | $908.6K |
| Current Assets | $11.76M | $12.61M | $11.69M | $9.26M | $9.25M | $8.34M | $7.97M | $9.96M | $8.07M | $7.36M |
| Total Assets | $15.18M | $16.24M | $15.36M | $12.87M | $12.95M | $11.36M | $10.97M | $12.71M | $10.89M | $10.17M |
| Current Liabilities | $3.21M | $4.58M | $4.52M | $2.46M | $2.45M | $3.07M | $2.80M | $3.24M | $3.43M | $2.85M |
| Long-term Debt | $138.5K | $138.3K | $139.2K | $140.2K | $141.0K | $144.3K | $146.6K | - | - | $172.6K |
| Total Liabilities | $3.72M | $5.16M | $5.16M | $3.21M | $3.29M | $3.47M | $3.28M | $3.93M | $4.01M | $3.50M |
| Stockholders' Equity | $11.46M | $11.08M | $10.19M | $9.66M | $9.66M | $7.88M | $7.70M | $8.79M | $6.88M | $6.67M |
| Retained Earnings | $1.96M | $1.76M | $1.06M | $720.7K | $966.3K | ($244.1K) | ($134.3K) | ($1.51M) | ($3.31M) | ($3.47M) |
Cash Flow
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($739.2K) | - | - | $897.3K | - | - | $397.2K | - |
| Investing Cash Flow | - | - | ($94.5K) | - | - | ($41.8K) | - | - | ($51.0K) | - |
| Financing Cash Flow | - | - | $150.5K | - | - | $39.4K | - | - | ($117.2K) | - |
| CapEx | - | - | $8.4K | $19.9K | $9.3K | - | - | - | $51.0K | $54.4K |
| Free Cash Flow | - | - | ($747.6K) | - | - | - | - | - | $346.2K | - |
Ratios
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 69.1% | 68.1% | 67.6% | 71.1% | 71.7% | 71.0% | 74.3% | 71.5% | 76.1% | 74.9% |
| Operating margin | 2.9% | 11.1% | 6.0% | 8.7% | 8.4% | -2.4% | 15.0% | -1.6% | 2.8% | 14.6% |
| EBITDA margin | 3.3% | 11.4% | 6.9% | 9.1% | 9.1% | -2.2% | 15.3% | -1.2% | 3.3% | 14.7% |
| Net margin | 2.8% | 8.7% | 4.9% | 8.2% | 8.3% | -1.9% | 12.1% | 12.1% | 2.5% | 10.8% |
| Free cash flow margin | - | - | -10.9% | - | - | - | - | - | 5.7% | - |
| FCF / Net income | - | - | -2.24 | - | - | - | - | - | 2.24 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 5.9% | 6.1% | 6.3% | 5.6% | 5.7% | 8.3% | 7.4% | 8.5% | 9.2% | 3.5% |
| Effective tax rate | 24.1% | 24.9% | 25.6% | 9.6% | 8.4% | - | 26.4% | - | 29.9% | 26.4% |
| Return on assets | 1.3% | 4.3% | 2.2% | 4.9% | 4.5% | -1.0% | 9.3% | 6.1% | 1.4% | 7.1% |
| Return on equity | 1.8% | 6.4% | 3.3% | 6.6% | 6.0% | -1.4% | 13.2% | 8.9% | 2.2% | 10.9% |
| Return on invested capital | 1.4% | 6.0% | 3.0% | 6.2% | 5.4% | -1.4% | 11.9% | - | - | 10.6% |
| Liquidity | ||||||||||
| Current ratio | 3.66 | 2.75 | 2.59 | 3.76 | 3.78 | 2.71 | 2.85 | 3.07 | 2.35 | 2.58 |
| Quick ratio | 2.44 | 1.72 | 1.73 | 2.73 | 2.66 | 1.65 | 1.63 | 2.01 | 1.75 | 2.12 |
| Cash ratio | 1.72 | 1.09 | 0.90 | 1.94 | 1.94 | 1.35 | 1.16 | 1.51 | 1.48 | 1.69 |
| Leverage | ||||||||||
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | - | - | 0.03 |
| Debt / Assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | - | - | 0.02 |
| Debt / EBITDA | 0.57 | 0.15 | 0.29 | 0.20 | 0.22 | - | 0.11 | - | - | 0.17 |
| Interest coverage | 149.3x | 692.5x | 320.9x | 519.2x | 390.0x | - | 770.7x | -69.5x | 105.7x | 561.3x |
| Equity multiplier | 1.32 | 1.47 | 1.51 | 1.33 | 1.34 | 1.44 | 1.43 | 1.45 | 1.58 | 1.52 |
| Liabilities / Assets | 0.24 | 0.32 | 0.34 | 0.25 | 0.25 | 0.31 | 0.30 | 0.31 | 0.37 | 0.34 |
| Efficiency | ||||||||||
| Asset turnover | 0.48 | 0.50 | 0.45 | 0.60 | 0.53 | 0.52 | 0.77 | 0.51 | 0.56 | 0.66 |
| Inventory turnover | 0.57 | 0.55 | 0.57 | 0.88 | 0.71 | 0.52 | 0.50 | 0.54 | 0.18 | 0.09 |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 637d | 663d | 639d | 414d | 512d | 704d | 732d | 681d | 2076d | 4245d |
| Days payable outstanding | 200d | 259d | 393d | 142d | 167d | 295d | 209d | 374d | 1080d | 2940d |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 5.4% | 5.2% | - | -8.2% | 7.0% | -4.2% | 25.1% | 14.4% | 627.6% | 1263.3% |
| Revenue CAGR (3y) | 8.8% | 6.5% | 3.9% | 150.2% | 144.0% | 179.3% | 135.6% | 160.7% | - | - |
| Revenue CAGR (5y) | 82.0% | 66.1% | 91.2% | - | - | 115.6% | 91.3% | 110.1% | - | 116.9% |
| Gross profit growth (YoY) | 1.5% | 0.7% | - | -12.1% | 7.4% | -10.6% | 24.2% | 9.6% | 877.7% | 1222.5% |
| Operating income growth (YoY) | -63.3% | 34.2% | - | -46.8% | - | - | 28.3% | - | - | - |
| Net income growth (YoY) | -64.8% | 11.2% | - | -37.8% | -26.2% | - | 40.1% | 382.0% | - | 2477.6% |
| EPS growth (YoY) | -71.4% | 12.5% | - | - | 75.0% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 18.7% | 14.7% | - | 25.5% | 9.9% | 14.6% | 15.3% | 50.0% | 1986.6% | 3512.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-05-31.
Business segments
$52.52M totalConsolidated$26.26M · 50.0%
Hearing Enhancement And Protection$24.74M · 47.1%
Hair Care And Skin Care$1.52M · 2.9%
Peer comparison
Same SIC group: Perfumes, Cosmetics & Other Toilet Preparations
Comparing Reviv3 Procare Co against the 5 most active filers in the same SIC group.